CIPLA Ltd posts consolidated PAT of Rs. 245.95 crore in Q4

CIPLA LTD. has reported financial results for the period ended March 31, 2020.

Financial Results (Q4 FY19-20) - QoQ Comparison

The company has reported total income of Rs.4469.37 crores during the period ended March 31, 2020 as compared to Rs.4443.13 crores during the period ended December 31, 2019.

The company has posted net profit / (loss) of Rs.245.95 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.351.03 crores for the period ended December 31, 2019.

The company has reported EPS of Rs.3.05 for the period ended March 31, 2020 as compared to Rs.4.35 for the period ended December 31, 2019.

Financials	Q4 FY19-20	Q3 FY19-20	% Change
Total Income	₹ 4469.37 crs	₹ 4443.13 crs	0.59%
Net Profit	₹ 245.95 crs	₹ 351.03 crs	-29.93%
EPS	₹ 3.05	₹ 4.35	-29.89%

Financial Results (Q4 FY19-20) - YoY Comparison

The company has reported total income of Rs.4469.37 crores during the period ended March 31, 2020 as compared to Rs.4499.34 crores during the period ended March 31, 2019.

The company has posted net profit / (loss) of Rs.245.95 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.367.20 crores for the period ended March 31, 2019.

The company has reported EPS of Rs.3.05 for the period ended March 31, 2020 as compared to Rs.4.55 for the period ended March 31, 2019.

Financials	Q4 FY19-20	Q4 FY18-19	% Change
Total Income	₹ 4469.37 crs	₹ 4499.34 crs	-0.67%
Net Profit	₹ 245.95 crs	₹ 367.20 crs	-33.02%
EPS	₹ 3.05	₹ 4.55	-32.97%

Financial Results (12 months ended FY 19-20) - YoY Comparison

The company has reported total income of Rs.17476.19 crores during the 12 months period ended March 31, 2020 as compared to Rs.16838.98 crores during the 12 months period ended March 31, 2019.

The company has posted net profit / (loss) of Rs.1546.52 crores for the 12 months period ended March 31, 2020 as against net profit / (loss) of Rs.1527.70 crores for the 12 months period ended March 31, 2019.

The company has reported EPS of Rs.19.16 for the 12 months period ended March 31, 2020 as compared to Rs.18.93 for the 12 months period ended March 31, 2019.

Financials	Year Ended FY19-20	Year Ended FY18-19	% Change
Total Income	₹ 17476.19 crs	₹ 16838.98 crs	3.78%
Net Profit	₹ 1546.52 crs	₹ 1527.70 crs	1.23%
EPS	₹ 19.16	₹18.93	1.22%

Umang Vohra, MD and Global CEO, Cipla Ltd said, "As the world endures the unprecedented COVID-19 pandemic, our foremost focus has been on safeguarding our employees and ensuring wellbeing of our patients. In support of the Government's efforts to combat the crisis, the company set-up an INR 25 crore 'Caring for Life' COVID-19 dedicated fund to support the healthcare ecosystem and communities. As a pharmaceutical company, it our constant endeavour to ensure that patients have access to life-saving drugs, we recently partnered with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir to treat COVID-19 patients upon approval. Our key markets continued to demonstrate strong growth momentum in the quarter. The USFDA approval for generic Albuterol MDI and the successful completion of the Phase 3 clinical study of generic Advair Diskus® has strengthened our respiratory franchise in the US market; furthering our aspirations of becoming the lung leaders of the world. As a 'new world' dawns post the pandemic, Cipla continues to uphold its pioneering legacy by reimagining healthcare and reinventing the ecosystem; all keeping the patient care at the core."

Shares of CIPLA LTD. was last trading in BSE at Rs.570.2 as compared to the previous close of Rs. 569.6. The total number of shares traded during the day was 360013 in over 8314 trades.

The stock hit an intraday high of Rs. 585 and intraday low of 565.9. The net turnover during the day was Rs. 206554749.

Source : Equity Bulls

Keywords